Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.
Hans-Joachim Schmoll
Consultant or Advisory Role - Bayer Schering Pharma; Roche/Genentech
Research Funding - Merck KGaA; Roche/Genentech
Karin Haustermans
Research Funding - Roche
Timothy Jay Price
Consultant or Advisory Role - Roche (U)
Bernard Nordlinger
No relevant relationships to disclose
Ralf Hofheinz
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Jean-Francois Daisne
No relevant relationships to disclose
Jozef Janssens
No relevant relationships to disclose
Baruch Brenner
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi
Peter Schmidt
No relevant relationships to disclose
Hans Reinel
No relevant relationships to disclose
Stephan Hollerbach
No relevant relationships to disclose
Karel Caca
No relevant relationships to disclose
Florian W.B. Fauth
No relevant relationships to disclose
Carla Hannig
No relevant relationships to disclose
John Raymond Zalcberg
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Roche; Sanofi
Other Remuneration - Roche; Sanofi
Niall C. Tebbutt
No relevant relationships to disclose
Murielle E. Mauer
No relevant relationships to disclose
Carlo G. M. Messina
No relevant relationships to disclose
Manfred P. Lutz
No relevant relationships to disclose
Eric Van Cutsem
Research Funding - Roche; Sanofi